Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2000-03-28
2002-09-17
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000, C530S399000, C536S023510, C435S173300, C435S320100, C435S252300, C435S252330, C930S120000
Reissue Patent
active
RE037850
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field Of The Invention
This invention relates to recombinant DNA-directed synthesis of certain proteins. More particularly, this invention relates to endothelial cell growth factor (ECGF), its recombinant DNA-directed synthesis, and ECGF's use in the treatment of endothelial cell damage and/or regeneration.
2. The Prior Art
Endothelial cell growth factor, referred to herein as “ECGF”, is a mitogen for endothelial cells in vitro. Growth of endothelial cells is a necessary step during the process of angiogenesis [Maciag,
Prog. Hemostasis and Thromb.,
7:167-182 (1984); Maciag, T., Hoover, G. A., and Weinstein, R.,
J. Biol. Chem.,
257: 5333-5336 (1982)]. Bovine ECGF has been isolated by Maciag, et al., [
Science
225:932-935 (1984)] using streptomycin sulfate precipitation, gel exclusion chromatography, ammonium sulfate precipitation and heparin-Sepharose affinity chromatography. Bovine ECGF purified in this manner yields a single-chain polypeptide which possesses an anionic isoelectric point and an apparent molecular weight of 20,000 [Maciag, supra; Schreiber, etal.,
J. Cell Biol.,
101:1623-1626 (1985); and Schreiber, et al.,
Proc. Natl. Acad. Sci.,
82:6138-6142 (1985)]. More recently, multiple forms of bovine ECGF have been isolated by Burgess, et al., [
J. Biol. Chem.
260:11389-11392 (1985)] by sodium chloride gradient elution of bovine ECGF from the heparin-Sepharose column or by reversed-phase high pressure liquid chromatography (HPLC). The two isolated polypeptides, designated alpha- and beta-ECGF have apparent molecular weights of 17,000 and 20,000, respectively. Using this procedure, the bovine ECGF contained in 8,500 ml of bovine brain extract (6.25×10
7
total units) is concentrated into a total of 6 ml of alpha-ECGF (3.0×10
6
units) and 3 ml of beta-ECGF (5.2×10
5
units). This is a 9,300-fold purification of alpha-ECGF and 16,300-fold purification of beta-ECGF (Burgess, supra). Recently, murine monoclonal antibodies against bovine ECGF have been produced (Maciag, et al., supra) which may be useful in purifying bovine ECGF in a manner similar to the monoclonal antibody purification of Factor VIIIC described by Zimmerman and Fulcher in U.S. Pat. No. 4,361,509.
In general, recombinant DNA techniques are known, see
Methods In Enzymology,
(Academic Press, New York) volumes 65 and 68 (1979); 100 and 101 (1983) and the references cited therein, all of which are incorporated herein by reference. An extensive technical discussion embodying most commonly used recombinant DNA methodologies can be found in Maniatis, et al.,
Molecular Cloning,
Cold Spring Harbor Laboratory (1982). Genes coding for various polypeptides may be cloned by incorporating a DNA fragment coding for the polypeptide in a recombinant DNA vehicle, e.g., bacterial or viral vectors, and transforming a suitable host. This host is typically an
Escherichia coli
(
E. coli
) strain, however, depending upon the desired product, eukaryotic hosts may be utilized. Clones incorporating the recombinant vectors are isolated and may be grown and used to produce the desired polypeptide on a large scale.
Several groups of workers have isolated mixtures of messenger RNA (mRNA) from eukaryotic cells and employed a series of enzymatic reactions to synthesize double-stranded DNA copies which are complementary to this mRNA mixture. In the first reaction, mRNA is transcribed into a single-stranded complementary DNA (ss-cDNA) by an RNA-directed DNA polymerase, also called reverse transcriptase. Reverse transcriptase synthesizes DNA in the 5′-3′direction, utilizes deoxyribonucleoside 5′-triphosphates as precursors, and requires both a template and a primer strand, the latter of which must have a free 3′-hydroxyl terminus. Reverse transcriptase products, whether partial or complete copies of the mRNA template, often possess short, partially double-stranded hairpins (“loops”) at their 3′ termini. In the second reaction, these “hairpin loops” can be exploited as primers for DNA polymerases. Preformed DNA is required both as a template and as a primer in the action of DNA polymerase. The DNA polymerase requires the presence of a DNA strand having a free 3′-hydroxyl group, to which new nucleotides are added to extend the chain in the 5′-3′ direction. The products of such sequential reverse transcriptase and DNA polymerase reactions still possess a loop at one end. The apex of the loop or “fold-point” of the double-stranded DNA, which has thus been created, is substantially a single-strand segment. In the third reaction, this single-strand segment is cleaved with the single-strand specific nuclease S1 to generate a “blunt-end” duplex DNA segment. This general method is applicable to any mRNA mixture, and is described by Buell, et al.,
J. Biol. Chem.,
253:2483 (1978).
The resulting double-stranded cDNA mixture (ds-cDNA) is inserted into cloning vehicles by any one of many known techniques, depending at least in part on the particular vehicle used. Various insertion methods are discussed in considerable detail in
Methods In Enzymology,
68:16-18 (1980), and the references cited therein.
Once the DNA segments are inserted, the cloning vehicle is used to transform a suitable host. These cloning vehicles usually impart an antibiotic resistance trait to the host. Such hosts are generally prokaryotic cells. At this point, only a few of the transformed or transfected hosts contain the desired cDNA. The sum of all transformed or transfected hosts constitutes a gene “library”. The overall ds-cDNA library created by this method provides a representative sample of the coding information present in the mRNA mixture used as the starting material.
If an appropriate oligonucleotide sequence is available, it can be used to identify clones of interest in the following manner. Individual transformed or transfected cells are grown as colonies on a nitrocellulose filter paper. These colonies are lysed; the DNA released is bound tightly to the filter paper by heating. The filter paper is then incubated with a labeled oligonucleotide probe which is complementary to the structural gene of interest. The probe hybridizes with the cDNA for which it is complementary, and is identified by autoradiography. The corresponding clones are characterized in order to identify one or a combination of clones which contain all of the structural information for the desired protein. The nucleic acid sequence coding for the protein of interest is isolated and reinserted into an expression vector. The expression vector brings the cloned gene under the regulatory control of specific prokaryotic or eukaryotic control elements which allow the efficient expression (transcription and translation) of the ds-cDNA. Thus, this general technique is only applicable to those proteins for which at least a portion of their amino acid or DNA sequence is known for which an oligonucleotide probe is available. See, generally, Maniatis, et al., supra.
More recently, methods have been developed to identify specific clones by probing bacterial colonies or phage plaques with antibodies specific for the encoded protein of interest. This method can only be used with “expression vector” cloning vehicles since elaboration of the protein product is required. The structural gene is inserted into the vector adjacent to regulatory gene sequences that control expression of the protein. The cells are lysed, either by chemical methods or by a function supplied by the host cell or vector, and the protein is detected by a specific antibody and a detection system such as enzyme immunoassay. An example of this is the lambda gt
11
system described by Young and Davis,
Proc. Nat'l. Acad. Sci. USA,
80:1194-1198 (1983) and Young and Davis,
Science,
222:778 (1983).
SUMMARY OF THE INVENTION
The present invention has made it possible to provide readily available, large quantities of ECGF or ECGF fragments. This has been achieved with oligonucleotides whose de
Burgess Wilson
Drohan William N.
Jaye Michael C.
Maciag Thomas
Aventis Pharmaceuticals Products Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Saoud Christine J.
LandOfFree
Recombinant human endothelial cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant human endothelial cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human endothelial cell growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2817668